Penguin Computing, a leading provider of on-demand High Performance Computing services in the cloud, and Numira Biosciences, a leader in 3D imaging solutions for Pre-Clinical Life Sciences, announced a formal partnership to bring graphics-intense data on-demand to Life Sciences customers. This unique platform will leverage a convergence of enabling technologies from Penguin Computing’s HPC as a Service offering, POD; Numira Biosciences’ AltaPortal product; and Nvidia’s GPU technology to deliver advanced pre-clinical imaging services to researchers at pharmaceutical and biotechnology companies around the globe.
Researchers will benefit from the cutting edge graphics, GPU power, global accessibility and reliability of Penguin Computing’s HPC as a Service platform, POD. Numira’s AltaPortal product provides a secure web interface for managing projects and exploring datasets, media and documents. By leveraging POD, AltaPortal will enable researchers to interactively navigate rich 3D data from microCT scans with overlaid analytics customized to the task at hand. The data will be delivered as a media stream to the client’s web browser, eliminating the need to transfer large and potentially proprietary datasets over networks, and allowing them to be secured in a central location.
“Penguin has enjoyed steady growth in the genomics sector with its POD offering. Adding Numira’s medical imaging software and services to our POD partner portfolio will enhance our breadth in the bioinformatics market and further establish POD as a destination for that set of users” said Matt Jacobs, SVP of Corporate Development for Penguin Computing.
“At Numira we’ve built our reputation delivering rich quantitative analytics for preclinical medical imaging. With our AltaPortal web service, we’re taking it to the next level; our customers will be able to interactively explore and quantitatively assess their preclinical imaging data with our custom 3D visual analytic tools. Penguin’s POD service offers the ideal platform for our rendering-on-demand engine,” said David Weinstein, Numira’s Chief Technology Officer.
About Numira Biosciences
Numira is a rapidly growing provider of specialty contract research services to the pharmaceutical and medical device industries. Through the combination of several novel technologies and capabilities, we provide clients with an unmatched array of pre-clinical services for their drug development programs in inflammation, cardiovascular, oncology, pulmonary, renal, bone, and others. Moreover, we are a recognized leader in high-resolution, 3D quantitative imaging and high-performance computing. Numira, a privately held company, is venture-backed by Signal Peak Ventures, the Tech Coast Angels, Pasadena Angels, and Crocker Ventures. For more information on Numira, please visit www.numirabio.com.